Endonovo Therapeutics, Inc. (ENDV)
OTCMKTS
· Delayed Price · Currency is USD
0.0002
0.00 (0.00%)
Apr 25, 2025, 11:55 AM EDT
Endonovo Therapeutics Revenue
Endonovo Therapeutics had revenue of $1.52K in the quarter ending September 30, 2023, a decrease of -86.13%. This brings the company's revenue in the last twelve months to $255.72K, up 1,699.85% year-over-year. In the year 2022, Endonovo Therapeutics had annual revenue of $135.36K with 85.15% growth.
Revenue (ttm)
255.72K
Revenue Growth
+1,699.85%
P/S Ratio
0.86
Revenue / Employee
255.72K
Employees
1
Market Cap
219.58K
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2022 | 135.36K | 62.25K | 85.15% |
Dec 31, 2021 | 73.11K | -92.69K | -55.91% |
Dec 31, 2020 | 165.80K | -144.37K | -46.55% |
Dec 31, 2019 | 310.16K | 226.90K | 272.51% |
Dec 31, 2018 | 83.26K | - | - |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Dec 31, 2013 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Endo Inc. | 1.76B |
Veradigm | 588.02M |
Glass House Brands | 200.90M |
Elite Pharmaceuticals | 70.00M |
Northwest Biotherapeutics | 1.38M |
BioStem Technologies | 301.83M |
American Oncology Network | 1.76B |
Silence Therapeutics | 43.26M |
Endonovo Therapeutics News
- 1 year ago - Endonovo Closes Asset Purchase Agreement for a Minimum of $50M With SofPulse, Inc - GlobeNewsWire
- 1 year ago - Endonovo's SofPulse® to Be Featured at Innovative Pain Management Solutions - GlobeNewsWire
- 1 year ago - Endonovo Signs Definitive Agreement to Sell SofPulse® Brand Business and IP to SofPulse Inc. for a minimum of $50 Million - GlobeNewsWire
- 1 year ago - Endonovo's SofPulse® Secures Taiwan FDA Approval - GlobeNewsWire
- 1 year ago - Endonovo's SofPulse® Secures Federal Supply Schedule Inclusion to Accelerate Expansion of VA Distribution - GlobeNewsWire
- 1 year ago - Endonovo's Breaking Barriers in With Patented Medical Technologies: 2023 Bi-Annual Update - GlobeNewsWire
- 2 years ago - Endonovo Pending Agreement to Develop Telehealth Division - GlobeNewsWire
- 2 years ago - Endonovo Launches SofPulse® into the Veterans Administration - GlobeNewsWire